The study is testing a new treatment for people with a type of breast cancer called triple-negative breast cancer (TNBC). TNBC is a cancer that tests negative for three common receptors (estrogen, progesterone, and HER2) that fuel most breast cancer growth. This study focuses on people whose cancer has returned, can't be removed by surgery, or has spread to other parts of the body. The treatment being tested combines a drug called Dato-DXd with or without another drug, Durvalumab, compared to standard chemotherapy with Pembrolizumab. The study aims to see which treatment helps patients live longer without their cancer getting worse and to understand the impact on their quality of life. Participants in this study must have TNBC that tests positive for PD-L1, a protein that can help cancer cells hide from the immune system. The study is open to both men and women who meet specific health criteria, but there are important rules about who can join, like not having certain other illnesses.

• The study compares three different treatment options.
• Participants must have a specific type of breast cancer.
• Safety and quality of life are key focus areas.